Drugs / Asimadoline
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01380561 | Jun → Jul 2011 | — | Tioga Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07042516 | Aug 2025 → Dec 2026 expected | — | Tioga Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT02475447 | Jul 2015 → Jun 2017 | atopic eczema | Tioga Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00454688 | Aug 2006 → Nov 2007 | irritable bowel syndrome | Tioga Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00955994 | Jan 2005 → Mar 2007 | irritable bowel syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01100684 | May 2010 → Jun 2013 | irritable bowel syndrome | Tioga Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00443040 Comparator | Jan 2007 → Feb 2008 | ileus | Tioga Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | asimadoline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01380561 ↗ |
| Known as | Asimadolina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1190199 ↗ |
| Known as | ASIMADOLINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1190199 ↗ |
| Known as | EMD-61753 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1190199 ↗ |
| Action | Activate | “The kappa opioid agonist, Asimadoline, reduces pain and discomfort and decreases gastrointestinal symptoms in participants with IBS.” NCT00955994 ↗1“Kappa opioid receptor agonist” CHEMBL1190199 ↗ |
| Modality | Small molecule | — CHEMBL1190199 ↗ |
| Route | Oral | “Asimadoline was administered orally, BID for 12 weeks” NCT00454688 ↗ |
| Target | OPRK1 | “Kappa opioid receptor agonist” CHEMBL1190199 ↗ |